Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a compounded combination drug consisting of bupivacaine, triamcinolone (typically as the acetonide), and sodium chloride. - **Bupivacaine** is an amide-type local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, preventing nerve impulse transmission and providing local or regional anesthesia[3][4][6]. - **Triamcinolone** is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties; it acts by binding to glucocorticoid receptors, modulating gene expression to suppress inflammation[8]. - **Sodium chloride** serves as an isotonic diluent or vehicle for injection. This combination is used primarily for pain management in procedures such as intra-articular injections or perioperative analgesia (e.g., after lumbar discectomy), where the local anesthetic provides immediate pain relief and the corticosteroid reduces inflammation over time[2][5]. The addition of sodium chloride ensures isotonicity for safe tissue administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + triamcinolone + sodium chloride.